الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - katte - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - katte - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. immunitetstrin har vist sig en uge efter primærvaccinationskursus for rhinotracheitis, calicivirus, chlamydophila felis og panleucopenia komponenter. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - katte - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a virus (inactivated), hepatitis b surface antigen - immunization; hepatitis b; hepatitis a - vacciner - twinrix pediatric er indiceret til brug hos ikke-immune børn, børn og unge fra et år til og med 15 år, der er i fare for både hepatitis-a og hepatitis-b-infektion.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

mcm vaccine b.v. - difteri toxoid, tetanus toxoid, bordetella pertussis antigener: kighoste toxoid, trådformede hæmagglutinin, pertactin, fimbriae typer 2 og 3, hepatitis b surface antigen, der er produceret i gær celler, poliovirus (inaktiveret): type 1 (mahoney), type 2 (mef-1), type 3 (saukett), produceret i vero celler/ haemophilus influenzae type b polysakkarid (polyribosylribitol fosfat), der er konjugeret til meningokok-protein. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - vacciner - vaxelis (dtap-hb-ipv-hib) er indiceret til primære og booster vaccination hos spædbørn og småbørn i alderen fra 6 uger, mod difteri, stivkrampe, kighoste, hepatitis b, polio og invasive sygdomme forårsaget af haemophilus influenzae type b (hib). brug af vaxelis bør være i overensstemmelse med officielle anbefalinger.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologiske stoffer til suidae - svin (slagtekyllinger) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d. active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection.  onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination.  duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination.  in addition, vaccination has been shown to reduce body weight gain losses under field conditions.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

zoetis belgium sa - porcint circovirus vaccine (inaktiverede, rekombinant) - immunologicals for suidae, inactivated viral vaccines - svin (slagtekyllinger) - til aktiv immunisering af svin fra 3 ugers alderen mod porcine circovirus type 2 (pcv2) for at reducere viral belastning i blod og lymfoide væv og fækalt afgivelse forårsaget af infektion med pcv2.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hele virion, inaktiveret, der indeholder antigen*: a/vietnam/1194/2004 (h5n1)* produceret i æg - influenza, human; immunization; disease outbreaks - vacciner - prophylax af influenza i en officielt erklæret pandemisk situation. pandemic influenza vaccine bør anvendes i overensstemmelse med officielle retningslinjer.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - a / indonesia / 05/2005 (h5n1) som brugt belastning (pr8-ibcdc-rg2) - influenza, human; immunization; disease outbreaks - vacciner - aktiv immunisering mod h5n1-subtype af influenza-a-virus. denne angivelse er baseret på immunogenicitet data fra raske forsøgspersoner i alderen fra 18 år og op efter administration af to doser af vaccinen tilberedes med h5n1 subtype stammer. prepandrix bør anvendes i overensstemmelse med officielle retningslinjer.

الاتحاد الأوروبي - الدانماركية - EMA (European Medicines Agency)

sanofi pasteur msd, snc - renset difteri toxoid, renset tetanus toxoid, renset kighoste toxoid, renset kighoste trådet hæmagglutinin, hepatitis b surface antigen, inaktiveret poliovirus type 1 (mahoney), inaktiveret poliovirus type 2 (mef 1), inaktiveret poliovirus type 3 (saukett), haemophilus influenzae type b polysakkarid - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vacciner - denne kombinerede vaccine er indiceret til primære og booster vaccination af børn mod difteri, stivkrampe, kighoste, hepatitis b forårsaget af alle kendte subtyper af vira, polio og invasive infektioner forårsaget af haemophilus influenzae type b.